IGM Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

IGM Biosciences wird ein jährliches Gewinn- und Umsatzwachstum von 3% bzw. 51.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -175.5% betragen.

Wichtige Informationen

3.0%

Wachstumsrate der Gewinne

11.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	51.8%
Zukünftige Eigenkapitalrendite	-175.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:IGMS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	13	-150	-155	-111	7
12/31/2025	7	-154	-143	-108	9
12/31/2024	3	-208	-175	-158	8
9/30/2024	3	-220	-173	-166	N/A
6/30/2024	3	-220	-176	-168	N/A
3/31/2024	2	-237	-195	-184	N/A
12/31/2023	2	-246	-205	-192	N/A
9/30/2023	2	-238	-196	-182	N/A
6/30/2023	2	-234	-196	-182	N/A
3/31/2023	2	-229	-29	-18	N/A
12/31/2022	1	-221	-16	-6	N/A
9/30/2022	1	-219	-13	-3	N/A
6/30/2022	0	-205	-6	3	N/A
3/31/2022	N/A	-185	-146	-136	N/A
12/31/2021	N/A	-165	-138	-125	N/A
9/30/2021	N/A	-139	-131	-112	N/A
6/30/2021	N/A	-115	-116	-93	N/A
3/31/2021	N/A	-95	-101	-79	N/A
12/31/2020	N/A	-81	-85	-68	N/A
9/30/2020	N/A	-72	-68	-57	N/A
6/30/2020	N/A	-61	-62	-57	N/A
3/31/2020	N/A	-53	-56	-53	N/A
12/31/2019	N/A	-43	-47	-45	N/A
9/30/2019	N/A	-37	-41	-39	N/A
6/30/2019	N/A	-34	-31	-30	N/A
3/31/2019	N/A	-27	-26	-24	N/A
12/31/2018	N/A	-23	-21	-20	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IGMS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IGMS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IGMS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IGMSDie Einnahmen des Unternehmens (51.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: IGMSDie Einnahmen des Unternehmens (51.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IGMS wird voraussichtlich in 3 Jahren unrentabel sein.

IGM Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 16%, EPS downgraded

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Consensus revenue estimates increase by 15%

Recent updates

Consensus revenue estimates increase by 16%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences: Waiting For Godot

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

IGM Biosciences, Inc. Provides Pipeline Updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 1,210%

IGM Biosciences: Unlikely To Move The Needle Again In 2024

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Share price stability

CEO, President & Director recently sold US$90k worth of stock

Consensus EPS estimates upgraded to US$3.26 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Consensus revenue estimates decrease by 13%, EPS upgraded

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IGM Biosciences, Inc. Announces Board Changes

Price target decreased by 7.8% to US$30.09

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Consensus revenue estimates decrease by 43%, EPS upgraded

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Consensus revenue estimates decrease by 50%

Price target decreased by 17% to US$32.64

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

CEO, President & Director recently sold US$235k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently bought US$1.0m worth of stock

Insufficient new directors

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer exercised options and sold US$548k worth of stock

Independent Chairman of the Board recently bought US$140k worth of stock

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Chief Scientific Officer exercised options and sold US$460k worth of stock

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Chief Scientific Officer exercised options and sold US$531k worth of stock

Price target decreased to US$43.78

Consensus revenue estimates fall by 98%

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Insufficient new directors

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought US$234k worth of stock

Consensus revenue estimates fall by 86%

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$60k worth of stock

Independent Director recently bought US$1.4m worth of stock

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$207k worth of stock

Price target decreased to US$57.89

IGM Biosciences: Interesting Science, Poor Trial Data

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?